Full video transcriptClick to expand
Auto-generated transcript of @madisonmulkey's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:09That would hurt more than the other ones.
@madisonmulkey's semaglutide progress claims, fact-checked
Quick answer
Semaglutide is a GLP-1 receptor agonist that slows gastric emptying and reduces appetite through effects on brain hunger signals. The STEP 1 trial found 14.9% weight loss at 68 weeks with 2.4mg weekly dosing combined with lifestyle counseling. Early visible changes often reflect reduced bloating and water retention rather than significant fat loss.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Semaglutide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 6 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For @madisonmulkey's semaglutide progress claims, fact-checked, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Efficacy of GLP-1 Receptor Agonists on Weight Loss, BMI, and Waist Circumference
A broad meta-analysis anchor for GLP-1 weight-loss effect and class-level comparisons.
PubMed
Discontinuing glucagon-like peptide-1 receptor agonists and body habitus
Used for pages discussing stopping therapy, weight regain, and long-term planning.
PubMed
Video claim decision path
Turn the claim into a safer next question
Direct answer
Compounded Semaglutide should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.
Evidence check
Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.
Safety check
A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.
Next step
If the claim matches your goal, use the get-started flow to move from curiosity into a supervised prescription review.
Claim path
Keep researching this semaglutide video claims cluster
Best for searchers comparing social semaglutide claims with GLP-1 eligibility, outcomes, and safety context.
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "@madisonmulkey's semaglutide progress claims, fact-checked" from Madison Mulkey. We read the clip as a GLP-1 social video fact-checks claim about Compounded Semaglutide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Semaglutide is a GLP-1 receptor agonist that slows gastric emptying and reduces appetite through effects on brain hunger signals.
The reason this review is not generic is the source wording and the canonical claim label "glp1 it crossed my mind that i should feel embarrassed about havi." In this clip, the useful excerpt is: "That would hurt more than the other ones." That wording changes the review because it points to Compounded Semaglutide safety, access, evidence, and fit, not a one-size-fits-all protocol.
The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Semaglutide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
Semaglutide is a GLP-1 receptor agonist that slows gastric emptying and reduces appetite through effects on brain hunger signals.
FormBlends verdict
Compounded Semaglutide safety, access, evidence, and fit
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with the Compounded Semaglutide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- Semaglutide is a GLP-1 receptor agonist that slows gastric emptying and reduces appetite through effects on brain hunger signals. The STEP 1 trial found 14.9% weight loss at 68 weeks with 2.4mg weekly dosing combined with lifestyle counseling. Early visible changes often reflect reduced bloating and water retention rather than significant fat loss.
- Semaglutide patients typically lose 2.6% of body weight by week 4 according to the STEP 1 trial
- Early visible changes often reflect reduced bloating and water retention, not just fat loss
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Semaglutide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Semaglutide guide, cost path, safety notes, and provider review before acting.
Review Compounded SemaglutideWhat You'll Learn
- Semaglutide patients typically lose 2.6% of body weight by week 4 according to the STEP 1 trial
- Early visible changes often reflect reduced bloating and water retention, not just fat loss
- Patients start on 0.25mg weekly and don't reach full 2.4mg dosing until week 16 or later
- Clinical trials combined semaglutide with lifestyle counseling, similar to this Weight Watchers approach
- Individual responses vary widely, with 83.5% of trial participants losing at least 5% of body weight
- Social media posts show dramatic results but rarely mention that 74% of users experience side effects
- The most significant weight loss typically occurs after months of treatment, not weeks
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What does this video actually claim?
Madison Mulkey (@madisonmulkey) shares her three-week progress on semaglutide, showing visible abdominal changes and expressing satisfaction with her weight loss results so far.
The video doesn't make specific medical claims about semaglutide's effectiveness or safety. Instead, it's a personal progress update that shows physical changes after starting the medication. Mulkey uses hashtags linking semaglutide to Weight Watchers, suggesting she's combining the medication with a structured eating program.
This type of before-and-after content is common on social media, but it raises questions about what kind of results people can realistically expect from GLP-1 medications in the first month of treatment.
Is three weeks enough time to see meaningful results?
Yes, but the most dramatic changes shown in videos like this are often temporary and related to reduced bloating rather than fat loss. Semaglutide works by slowing gastric emptying and reducing appetite, which can lead to visible abdominal changes within days.
The STEP 1 trial (Wilding et al., NEJM, 2021) found that participants lost an average of 2.6% of their body weight by week 4 on semaglutide 2.4mg. For someone weighing 180 pounds, that's about 4.7 pounds. However, patients start on a much lower dose (0.25mg) and don't reach the full therapeutic dose until week 16 or later.
Much of the early visual change comes from reduced water retention and less food volume in the digestive system. The SUSTAIN-1 trial (Sorli et al., Diabetes Care, 2017) showed that gastrointestinal effects like reduced bloating occurred within the first two weeks of treatment.
What role does Weight Watchers play here?
Combining semaglutide with a structured eating program like Weight Watchers likely accelerates early results, but it makes it impossible to attribute changes to the medication alone.
Weight Watchers now offers semaglutide through their clinical program, but their points-based system can create additional caloric restriction beyond what the medication provides. This combination approach mirrors the clinical trials, which included lifestyle counseling.
The STEP 1 trial included monthly lifestyle intervention sessions along with semaglutide. Participants who received semaglutide plus lifestyle counseling lost 14.9% of body weight at 68 weeks, compared to 2.4% in the placebo group. However, teasing apart the individual contributions of medication versus behavior change remains difficult.
Should you expect similar results?
Maybe, but individual responses to semaglutide vary significantly, and social media posts tend to show the most dramatic outcomes rather than typical experiences.
The STEP trials showed that about 83.5% of participants lost at least 5% of their body weight, but response rates varied widely. Some people lost over 20% of their starting weight, while others saw minimal changes. Factors like starting BMI, insulin sensitivity, and adherence to lifestyle changes all influence outcomes.
Posts like Mulkey's represent individual experiences, not clinical evidence. The visual changes she shows could reflect anywhere from 2-8 pounds of weight loss, plus reduced bloating and improved posture for photos. That's within the expected range for early semaglutide treatment, but it's not guaranteed for everyone.
More concerning is that these posts rarely mention side effects, which affect up to 74% of people taking semaglutide according to the STEP trials.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Madison Mulkey · TikTok creator
217.9K views on this video
It crossed my mind that I should feel embarrassed about having my stomach out on the internet but I’m just not. I want to fully share this journey with y’all and that includes this. I’m starting week
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about semaglutide patients typically lose 2.6% of body weight by week?
Semaglutide patients typically lose 2.6% of body weight by week 4 according to the STEP 1 trial
What does the video say about early visible changes often reflect reduced bloating?
Early visible changes often reflect reduced bloating and water retention, not just fat loss
What does the video say about patients start on 0.25mg weekly?
Patients start on 0.25mg weekly and don't reach full 2.4mg dosing until week 16 or later
What does the video say about clinical trials combined semaglutide with lifestyle counseling, similar to this?
Clinical trials combined semaglutide with lifestyle counseling, similar to this Weight Watchers approach
What does the video say about individual responses vary widely, with 83.5% of trial participants losing?
Individual responses vary widely, with 83.5% of trial participants losing at least 5% of body weight
What does the video say about social media posts show dramatic results?
Social media posts show dramatic results but rarely mention that 74% of users experience side effects
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Madison Mulkey, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.